Home
HEALTH CARE
Allergy and hay fever
Antineoplastic and immunomodulating agents
Circulatory system
Colds and flu
Dermatology
Digestive system
Eyes
For diabetics
Homeopathy
Musculoskeletal system
Non-sex hormones
Nutrikosmetics
Pain
Preparations for the treatment of infections
Sex and contraception
The immune system
The nervous system
Urogenital tract
Vitamins and minerals
HEALTHY LIFESTYLE
For athletes
Healthy food
Slimming
HYGIENE
Disinfection
Ear hygiene
Hot and cold compresses
Intimate hygiene
Laundry products
Oral hygiene
Slices and sticks
Urinary incontinence
COSMETICS
Cosmetic articles
For eyelashes and eyebrows
For face
For hair
For hands and nails
For the body
Soap
Sunbathing
To the feet
To the mouth
FOR HIM
Cosmetics for men
Health
PREGNANCY AND MOTHERHOOD
Accessories
Cosmetics for pregnant women
Health in pregnancy
Supporting fertility
CHILD
Baby nutrition
Child health
Cosmetics for children
Hygiene items for children
Oral hygiene (for children)
Scrolling
HEALTH CARE
Espa-Tibol 2.5mg 28 tablets — Made in Germany — Free Delivery
Espa-Tibol 2.5mg 28 tablets — Made in Germany — Free Delivery
Brand:
Lindopharm GmbH
Product Code:
Espa-Tibol
Availability:
In Stock
$27.65
Add to Cart
Description
Product description
Espa-tibol tablets are used to treat symptoms of estrogen deficiency in postmenopausal women if menopause has occurred more than 1 year ago.
The decision to prescribe tibolone should be based on an assessment of individual risk factors; when prescribing to patients over the age of 60, the risk of stroke should be taken into account.
Compound
The active substance is tibolone (one tablet contains tibolone 2.5 mg).
Excipients: potato starch, magnesium stearate, ascorbyl palmitate, lactose monohydrate.
Contraindications
hypersensitivity to the active substance or to any of the excipients;
pregnancy and lactation period;
suspicion of breast cancer, its current or history (the preparation increased the risk of recurrence of breast cancer in a placebo-controlled study);
suspected or existing estrogen-dependent tumors (eg endometrial cancer);
vaginal bleeding of unknown etiology;
untreated endometrial hyperplasia;
venous thromboembolism in history or at present (deep vein thrombosis, pulmonary embolism);
history of arterial thromboembolic diseases (for example, angina pectoris, myocardial infarction, stroke, or transient ischemic cerebrovascular accident);
acute liver disease or a history of liver disease, until normalization of liver function tests;
porphyria.
Mode of application
The recommended dose is one tablet per day. There is no need for dose adjustment for elderly patients. Take the tablets with a small amount of water or other drinks, preferably at the same time of day. To initiate and continue treatment for postmenopausal symptoms, the lowest effective dose should be used for the shortest period of time. When treating with Espatibol, progestogens should not be used separately.
The beginning of the use of the preparation "Espatibol". Women with natural menopause are advised to start treatment with Espatibol no earlier than 12 months after the last natural bleeding. In the case of menopause that occurred after surgery, treatment with Espatibol can be started immediately.
Before you start taking Espatibol, the cause of any irregular / unscheduled vaginal bleeding, including when using hormone replacement therapy (HRT), must be determined to exclude a malignant neoplasm.
Application features
Drivers
The preparation does not affect the reaction rate when driving vehicles or working with other mechanisms.
Overdose
The acute toxicity of tibolone in animals is very low. Therefore, the appearance of symptoms of toxicity is expected, even when taking several tablets at the same time. In acute overdose, a woman may experience nausea, vomiting, and vaginal bleeding. There is no specific antidote. If necessary, symptomatic therapy should be carried out.
Side effects
The following adverse reactions were reported during the 21st placebo-controlled study (including the LIFT studies), with the participation of 4079 women who received therapeutic doses of tibolone (1.25 or 2.5 mg), as well as 3476 women who received placebo. The duration of treatment in these studies ranged from 2 months to 4.5 years.
The following are the adverse reactions that occur in the treatment of tibolone significantly more often than when taking placebo.
From the gastrointestinal tract: often (> 1%, < 10%) - pain in the lower abdomen.
From the skin and subcutaneous tissue: often (> 1%, < 10%) - pathological hair growth.
From the reproductive system and mammary glands: often (> 1%, < 10%) - vaginal discharge, thickening of the walls of the endometrium, postmenopausal bleeding, discomfort in the mammary glands, itching of the genital organs, vaginal candidiasis, vaginal bleeding, pain in the pelvic area, cervical dysplasia, vulvovaginitis.
Examination: often (> 1%, < 10%) - weight gain, abnormal cervical smear results.
Storage conditions
Store at a temperature not exceeding 25 ° C, out of the reach of children.
Shelf life - 30 months.
0 reviews
There are no reviews for this product.